Background: Eravacycline (ERV) is a novel, fully-synthetic fl uorocycline antibiotic of the tetracycline class with in vitro activity against Gram-negative pathogens, including extendedspectrum β-lactamase and carbapenemase-producing Enterobacteriaceae (ENT) as well as multidrug-resistant strains of Acinetobacter baumannii. To further characterize its activity in vitro, ERV was tested against new reference panels made available by the FDA and CDC for the testing of new antibacterial agents. Methods: Using Clinical Laboratory Standards Institute methodology, minimal inhibitory concentration (MIC) values for antibiotics were determined for isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank (AR Bank) panels: 1) ENT Carbapenem Breakpoint Panel ("Breakpoint"), 2) Gram Negative Carbapenemase Detection Panel ("Detection") and 3) ENT Carbapenemase Diversity Panel ("Diversity"). The Breakpoint panel contained 31 ENT of which 7 were meropenem-resistant, including 5 bla KPC isolates. The Detection panel was comprised of 80 isolates total; a 52 ENT subset contained carbapenemase genes bla IMP (n=1), bla KPC (n=8), bla NDM (n=10), bla OXA (n=5), bla SME (n=2), bla VIM (n=3). The Diversity panel contained 53 ENT with carbapenemase genes bla IMI (n=2), bla IMP (n=1), bla KPC (n=18), bla NDM (n=20), bla OXA (n=5), bla SME (n=6), and bla VIM (n=2). There were 14 A. baumannii isolates across all panels, of which 4 isolates had bla NDM and 8 had bla OXA genes. Results: The ERV MIC 50/90 values and ranges against the Breakpoint, Detection (ENT subset), Diversity panels and A. baumannii isolates are shown in the Table. 
Background
Eravacycline (ERV) is a novel, fully-synthetic fl uorocycline antibiotic of the tetracycline class in clinical development for treatment of intraabdominal and urinary tract infections, including those caused by multidrug-resistant Gram negative pathogens. Eravacycline has historically exhibited potent in vitro activity against Gram-negative pathogens, including extended-spectrum β-lactamase and carbapenemaseproducing Enterobacteriaceae as well as multidrug-resistant strains of Acinetobacter baumannii. To further characterize this in vitro activity, ERV was tested against reference panels made available by the FDA and CDC for the testing of new antibacterial agents.
Methods
Using Clinical and Laboratory Standards Institute (CLSI) methodology (CLSI 2015; CLSI 2016), minimal inhibitory concentration (MIC) values for antibiotics were determined for isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank panels: 1) Enterobacteriaceae Carbapenem Breakpoint Panel ("Breakpoint"), 2) Gram-Negative Carbapenemase Detection Panel ("Detection") and 3) Enterobacteriaceae Carbapenemase Diversity Panel ("Diversity"). The Breakpoint panel contained 31 Enterobacteriaceae isolates, of which 7 were meropenemresistant, including 5 bla KPC isolates. The Detection panel was comprised of 80 isolates total; a 54 Enterobacteriaceae subset contained carbapenemase genes bla IMP (n=2), bla KPC (n=9), bla NDM (n=10), bla OXA (n=5), bla SME (n=2), bla VIM (n=3). The Diversity panel contained 53 Enterobacteriaceae with carbapenemase genes bla IMI (n=2), bla IMP (n=1), bla KPC (n=18), bla NDM (n=20), bla OXA (n=5), bla SME (n=6), and bla VIM (n=2). There were 14 A. baumannii isolates across all panels, of which 4 isolates had bla NDM and 8 had bla OXA genes.
Beta-lactam antibiotic resistance classifi cations are listed as reported by the CDC. Isolates with tetracycline resistance were screened for the presence of tetracycline-specifi c resistance genes by PCR using published methodology (Grossman et al. 2012; Sutcliffe et al. 2013 ). Further, isolates of Klebsiella pneumoniae with elevated tigecycline and/or tetracycline-class antibiotic MIC values were screened for sequence variations in genes known to be associated with tigecycline non-susceptibility, namely the regulatory genes ramR, acrR, and oqxR, and rpsJ, which encodes ribosomal protein S10 (Bratu et 
Results

Conclusions
Eravacycline maintained potency against carbapenemresistant Enterobacteriaceae and A. baumannii isolates in the CDC Antimicrobial Resistance Bank, including those containing carbapenemase genes prevalent in contemporary clinical isolates.
The eravacycline MIC 50/90 values and ranges against the full Breakpoint, Detection, and Diversity panels as well as subsets thereof are shown in Table 1 . Overall, eravacycline maintained potency against isolates of Enterobacteriaceae and A. baumannii. The MIC 50/90 values for eravacycline against the Breakpoint and Diversity panels were 0.25/1 μg/ml and 0.5/1 μg/ml, the later a two-fold improvement over tigecycline. Against the Detection panel eravacycline maintained an MIC 50/90 of 0.5/2 μg/ml against isolates of Enterobacteriaceae alone, and 0.25/2 μg/ml against the total pool of Enterobacteriaceae and A. baumannii isolates, however, the eravacycline MIC values against the P. aeruginosa isolates (excluded from table, n=12) ranged from 2 to >32 μg/ml. Against the sum total of 138 Enterobacteriaceae and 14 A. baumannii eravacycline maintained an MIC 50/90 of 0.25/2 and 0.25/1 μg/ml, respectively.
The presence of various beta-lactamase resistance mechanisms did not impact the activity of eravacycline against isolates of Enterobacteriaceae. Across all Enterobacteriaceae carrying the bla NDM (n=30) and bla KPC (n=32) genes, two major carbapenem resistance mechanisms, eravacycline remained potent, maintaining MIC 50/90 values of 0.5/2 μg/ml and 0.25/2 μg/ml, respectively. Similarly, against a total of 49 isolates carrying one or more of the tetracycline-specifi c effl ux pump genes tet(A), tet(B), tet(C), or tet(D), eravacycline showed an MIC 50/90 of 0.5/2 μg/ml, while in isolates of K. pneumoniae carrying sequence variants of genes known to be associated with reduced susceptibility to tigecycline (n=17), eravacycline showed a modestly reduced susceptibility with an MIC 50/90 of 1/4 μg/ml.
Beta-lactam resistance mechanisms did not impact the activity of eravacycline against isolates of A. baumannii with MIC values ranging from 0.031 to 1 μg/ml for isolates carrying bla NDM (n=4), bla OXA (n=8), and/or tetracycline-specifi c resistance genes (n=8), maintaining four-fold potency over tigecycline MIC ranges in each set of isolates. n/a n/a n/a n/a (0. 125 8 n/a n/a n/a n/a (0.063 0.5) (0.125 1) (4 >32) (0. 125 8) n/a n/a n/a n/a (0.125 2) (0.25 2) (4 >32) (0. 25 8) n/a n/a n/a n/a
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